Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 11th Global
Gastroenterologists Meeting Hotel Holiday Inn Rome Aurelia Via Aurelia Km 8400, Rome, Italy.

Day 1 :

Keynote Forum

Francesco Marotta

ReGenera Research Group for Aging Intervention, Italy & MMC Clinic - Gender Medicine Unit by Genomics & Biotechnology, Milano, Italy

Keynote: Hormetic Microbiota effect on the gut-based mechanism of Metformin benefit

Time : 09:00-09:40

OMICS International Gastro 2017 International Conference Keynote Speaker Francesco Marotta photo
Biography:

Francesco Marotta MD, Ph.D. with experience in gastroenterology, oxidative stress, aging and nutrigenomics in the USA, Cape-Town, and Japan leading to extensive publications. Hon. Research Professor at Dept of Nutrition, Texas Women University, USA, Advisory Board Panel of the Center for Life Science at Nazarbayev University, Astana, Kazakhstan and External Examiner at McGill and Osaka Universities ( Canada and Japan). Currently, he serves as CMO at Milano Medical center for Healthy Aging and also at a prime international clinical set up in Central-Asia,

Abstract:

Metformin is commonly used as the first line of medication for the treatment of metabolic syndromes, such as obesity and type 2 diabetes (T2D). Recently this compound has gained an increasing interest within the scenario of pro-longevity medicine given also its peculiar increase in AMP-activated protein kinase (AMPK) thus beneficially affecting  energy balance by help maintaining a proper cellular AMP/ATP ratio through the increase of ATP consumption and decreasing ATP production, which is associated with AMPK activation.
The gut microbiota is known to play an important role in harvesting energy from food, metabolic processes, and immune modulation. An increasingly body of evidence proves that its composition is significantly associated with obesity, T2D, metabolic syndromes and other chronic diseases. 
Data show that when metformin is administered to high fat diet (HFD) animals, the composition of the phylum Bacteroidetes significantly increases (over 75%)  similar to that in the normal diet-(ND)-fed animals. Moreover, the composition of Verrucomicrobia in the HFDMet group significantly increases, unlike what obtained by simple dietary change applied to HFD. In the HFD-Met group, the abundances of the families Bacteroidaceae, Verrucomicrobiaceae, and some specific Clostridia change significantly vs those in the HFD and HFD-ND groups. Interestingly, Metformin treatment also affects the composition of the gut microbiota in mice fed a ND. The families Rikenellaceae, Ruminococcaceae, and Verrucomicrobiaceae, as well as Alistipes spp., Akkermansia spp., and Clostridium spp., are more abundant in the ND-Met group than the ND group. All this is starting shedding new light on the AMPK-independent pathway of metabolic improvement by metformin treatment through targeting the microbiota. It is likely that metformin via changes in Akkermansia and Lactobacilli bacteria regulation  improves the metabolic profile of diet-induced obesity by ameliorating low-grade tissue inflammation and also upregulating the intestinal expression of several endocannabinoids controlling inflammation, barrier function and peptide secretion in the gut.
Till recently, the main hindrance in bacterial stool culture is represented by the major bias that only a few gut bacteria can be properly detected and cultivated in the laboratory. On the other hand, capillary sequencing or PCR-based approaches need culture medium with its inner complexities of multiple separate analysis. In this scenario, a rising star is represented by the next-generation sequencing (NGS) which, by combining multiple samples in a sequencing run, is able to analyse the entire microbial community within a sample. Thus this unique ability enables  to catalog resident organisms within the very complex gut polymicrobial bacterial communities to make a DNA-stable sampling and producing a report intelligible to physicians and ideally endowed with a nutritionist and a gastroenterologist commented interplay so to make it a valid diagnostic, a treatment-guided result and a follow-up tool as well. This has been quite recently achieved by a spin-off of dedicated geneticists and biologists (Next Genomics, Prato, Italy)  using a kit allowing small and 14-day stavle sampling of  0,0001% accuracy. This test is currently used also in the clinical center (MMC Milano, Milan, Italy) helping to identify the enterotype and the presence of bacterial species correlated with diseases.
 

 

Keynote Forum

Larry I Good

Good Pharmaceutical Development Company, USA

Keynote: Serum derived bovine immunoglobulin in the treatment of gastrointestinal disease

Time : 09:40-10:20

OMICS International Gastro 2017 International Conference Keynote Speaker Larry I Good photo
Biography:

Dr. Larry Good has been a practicing gastroenterologist since 1978. Dr. Good graduated Colgate University Magna Cum Laude in 1969 and received his M.D. with Alpha Omega Alpha status from the Medical University of South Carolina in Charleston, SC in 1973.

Dr. Good served a medical residency from 1973-76 and was Chief Medical Resident in 1976. He was fellowship trained in gastroenterology from 1976-78.

Dr. Good has served as the Director of Liver Diseases at Nassau County Medical Center and was for many years Chief, Division of Gastroenterology, Department of Medicine at South Nassau Communities Hospital. Dr. Good is an assistant clinical professor of medicine at SUNY Stony Brook. He has given hundreds of lectures in his field and has authored numerous papers and abstracts. Recently, Dr. Good presented the ACG Theater lecture at the American College of Gastroenterology annual meeting in Chicago, Illinois in October, 2014.

Dr. Good was Chief Medical Officer at Ritter Pharmaceuticals in Los Angeles, California, where he expanded his research interest in the intestinal microbiome. Dr. Good’s current clinical research activities involve the microbiome, inflammatory bowel disease, irritable bowel syndrome and the application of orally administered gamma globulin to patients with acute and chronic gastro-intestinal disorders.

Abstract:

Serum derived bovine immunoglobulin was introduced as a medical food in the U.S. in 2013. Since then it has been studied in over 800 patients with a variety of gastrointestinal illnesses including diarrhea predominant irritable bowel syndrome (IBS-D), ulcerative colitis, Crohn’s disease, pouchitis, C. difficile colitis and chronic mesenteric ischemia. Its effectiveness in these diverse disease entities is related to the ability of SBI to bind intraluminal pro-inflammatory mediators including enterotoxins, pro-inflammatory cytokines and bacterial degradation products, thereby, preventing the loss of intercellular tight junction proteins. By maintaining tight junction, integrity, dendritic antigenic stimulation in the mucosa is reduced, resulting in inhibition of the inflammatory cascade.           This presentation will review the US FDA category of medical foods, the proposed mechanism of action SBI and published clinical data.